Prescription ·Strong evidence ·Reviewed May 2026
Valsartan is an ARB with evidence from the Val-HeFT and VALIANT trials for heart failure and post-MI management. It is also a key component of the combination drug sacubitril/valsartan (Entresto), which has revolutionized heart failure treatment.
The bottom line
Evidence rating strong. Most-documented uses: effective blood pressure reduction, reduces hospitalizations in heart failure (val-heft), non-inferior to captopril post-mi (valiant). 10 sources indexed (2010–2024), with 4 interaction records on file.
Core mechanism
Selectively blocks the AT1 receptor, preventing the vasoconstrictive, aldosterone-releasing, and growth-promoting effects of angiotensin II. Does not inhibit ACE or affect bradykinin, resulting in better tolerability regarding cough. Reduces preload, afterload, and cardiac remodeling in heart failure.6
Can be taken with or without food; food reduces Cmax by ~40% and AUC by ~50%, but clinical significance is minimal at steady state
Nutrients this medication can lower over time, and what to replace.
ARB therapy can modestly increase urinary zinc losses in some users, though typically less than ACE inhibitors.
Valsartan blocks AT1 receptors, reducing aldosterone and potassium excretion. Potassium supplementation creates hyperkalemia risk.
Recommendation: Avoid potassium supplements with valsartan unless prescribed with close monitoring.
Valsartan reduces sodium reabsorption through AT1 receptor blockade and lowers glomerular filtration, which causes the kidney to retain lithium. Multiple case reports describe prescription-lithium patients developing toxicity within weeks of starting or increasing valsartan, sometimes at previously safe doses. Lithium Orotate doses are smaller, but the same renal handling applies and the margin to neurotoxicity is narrow.
Recommendation: Avoid Lithium Orotate while taking valsartan. If you must combine them, keep the dose low, stay well hydrated, and ask your prescriber to check a serum lithium level after 1-2 weeks. Hold the supplement during any vomiting, diarrhea, or fever.
A systematic review of zinc and antihypertensive therapy reported that valsartan reduced erythrocyte and plasma zinc concentrations in treated hypertensives. The effect is smaller than with sulfhydryl-containing ACE inhibitors but still meaningful over chronic use. Symptoms of zinc deficiency include altered taste, slow wound healing, hair loss, and reduced immune function.
Recommendation: If you take valsartan long term, a modest zinc supplement (15-30 mg/day) or a multivitamin containing zinc is reasonable, especially if you notice altered taste or recurrent infections. Take zinc with food to limit GI upset.
Garlic Extract lowers blood pressure modestly. When combined with the ARB valsartan, the effects are additive, which can help patients with uncontrolled hypertension but may produce mild hypotension if blood pressure is already at goal.
Recommendation: If your blood pressure is already well controlled on valsartan, monitor at home before and after starting Garlic Extract. Typical aged garlic doses are 600-1200 mg/day. Tell your prescriber so your valsartan dose can be adjusted if needed.
Numbered references. Citations throughout the page link here.
Xu Q, Shen Y, Zhao J et al.. Salvianolate injection for hypertensive nephropathy patients who were using valsartan: A systematic review and meta-analysis. Frontiers in pharmacology. 2023
Takagi H, Niwa M, Mizuno Y et al.. A meta-analysis of randomized trials of telmisartan vs. valsartan therapy for blood pressure reduction. Hypertension research : official journal of the Japanese Society of Hypertension. 2013
Eckert S, Freytag SB, Müller A et al.. Meta-analysis of three observational studies of amlodipine/valsartan in hypertensive patients with additional risk factors. Blood pressure. 2013
Zheng Z, Lin S, Shi H. A systematic review and meta-analysis of telmisartan versus valsartan in the management of essential hypertension. Journal of clinical hypertension (Greenwich, Conn.). 2010
Qu H, Shen AL, Yang K et al.. Efficacy and safety of Qingda granule versus valsartan capsule in Chinese grade 1 hypertensive patients with low-moderate risk: A randomized, double-blind, double dummy, non-inferiority, multi-center trial. Pharmacological research. 2024
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack